UK Promises Reduced Trial Burden For Biosimilars

MHRA Sets Out Plans For ‘Innovative’ Procedure After EU Transition

 
• By David Wallace
Heavy box
The MHRA is planning to reduce the trial burden for biosimilars • Source: Shutterstock

More from Regulation

More from Policy & Regulation